Menopause and hormone therapy: From vascular endothelial function to cardiovascular disease

Hellenic Journal of Cardiology

Volumn 50, Issue 4, 2009, Pages 303-315

  Bechlioulis, Aris ^a   Naka, Katerina K ^a   Papanikolaou, Odysseas ^a   Kontostolis, Emmanouil ^a   Kalantaridou, Sophia N ^a   Michalis, Lampros K ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Atherosclerosis; Early menopausal women; Flow mediated dilation; Oestrogen

Indexed keywords

ALPHA TOCOPHEROL; CONJUGATED ESTROGEN; CYPROTERONE ACETATE PLUS ESTRADIOL VALERATE; ESTRADIOL; ESTROGEN; ESTROGEN PLUS PROGESTERONE; MEDROXYPROGESTERONE ACETATE; MICRONISED PROGESTERONE; NORETHISTERONE ACETATE; PROGESTERONE; PROGESTERONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTERY BLOOD FLOW; ARTERY DILATATION; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLIMACTERIUM; CLINICAL TRIAL; DRUG DOSE COMPARISON; ENDOTHELIAL DYSFUNCTION; ESTROGEN ACTIVITY; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; MENOPAUSE; PREMATURE OVARIAN FAILURE; REVIEW; RISK ASSESSMENT; VASCULAR ENDOTHELIUM;

CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; RISK FACTORS;

EID: 67749095243     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (166)

1. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med. 1987; 316: 1105-1110. (Pubitemid 17052498)
2. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med. 1993; 329: 247-256.
3. Stramba-Badiale M, Fox KM, Priori SG, et al. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J. 2006; 27: 994-1005.
4. Varas-Lorenzo C, Garcia-Rodriguez LA, Perez-Gutthann S, Duque-Oliart A. Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study. Circulation. 2000; 101: 2572-2578.
5. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000; 133: 933-941. (Pubitemid 32003509)
6. Ferrara A, Quesenberry CP, Karter AJ, Njoroge CW, Jacobson AS, Selby JV. Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanente Diabetes Registry, 1995-1998. Circulation. 2003; 107: 43-48.
7. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI trial. JAMA. 1995; 273: 199-208.
8. Sack MN, Rader DJ, Cannon RO, 3rd. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet. 1994; 343: 269-270.
9. Koh KK, Son JW, Ahn JY, et al. Effect of hormone replacement therapy on nitric oxide bioactivity and monocyte chemoattractant protein-1 levels. Int J Cardiol. 2001; 81: 43-50. (Pubitemid 33022660)
10. Wagner JD, Clarkson TB, St Clair RW, Schwenke DC, Shively CA, Adams MR. Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest. 1991; 88: 1995-2002.
11. Wagner JD, Clarkson TB. The applicability of hormonal effects on atherosclerosis in animals to heart disease in postmenopausal women. Semin Reprod Med. 2005; 23: 149-156.
12. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998; 280: 605-613.
13. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000; 343: 522-529. (Pubitemid 30650747)
14. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001; 345: 1243-1249. (Pubitemid 34951488)
15. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-333.
16. Cherry N, Gilmour K, Hannaford P, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet. 2002; 360: 2001-2008. (Pubitemid 36026578)
17. Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofiel PM. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJOG. 2002; 109: 1056-1062. (Pubitemid 35279139)
18. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003; 349: 523-534. (Pubitemid 36951364)
19. Mendelsohn ME, Karas RH. HRT and the young at heart. N Engl J Med. 2007; 356: 2639-2641.
20. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004; 109 (23 Suppl 1): III27-32.
21. Henderson A. Endothelial dysfunction: a reversible clinical measure of atherogenic susceptibility and cardiovascular inefficiency. Int J Cardiol. 1997; 62 (Suppl 1): S43-48. (Pubitemid 28044495)
22. Karatzis EN. The role of inflammatory agents in endothelial function and their contribution to atherosclerosis. Hellenic J Cardiol. 2005; 46: 232-239. (Pubitemid 41664060)
23. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340: 115-126.
24. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992; 340: 1111-1115.
25. Vita JA. Endothelial function and clinical outcome. Heart. 2005; 91: 1278-1279.
26. Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle- brachial pressure index. Circulation. 2003; 108: 2093-2098. (Pubitemid 37337585)
27. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol. 2002; 40: 505-510. (Pubitemid 34833167)
28. Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation. 2007; 115: 2390-2397. (Pubitemid 46717961)
29. Herrington DM, Espeland MA, Crouse JR, et al. Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Arterioscler Thromb Vasc Biol. 2001; 21: 1955-1961. (Pubitemid 34219747)
30. Koh KK, Kang MH, Jin DK, et al. Vascular effects of estrogen in type II diabetic postmenopausal women. J Am Coll Cardiol. 2001; 38: 1409-1415.
31. Santoro N. The menopause transition: an update. Hum Reprod Update. 2002; 8: 155-160.
32. Grady D. Clinical practice. Management of menopausal symptoms. N Engl J Med. 2006; 355: 2338-2347.
33. De Aloysio D, Gambacciani M, Meschia M, et al. The effect of menopause on blood lipid and lipoprotein levels. Atherosclerosis. 1999; 147: 147-153. (Pubitemid 29486784)
34. Graff-Iversen S, Thelle DS, Hammar N. Serum lipids, blood pressure and body weight around the age of the menopause. Eur J Cardiovasc Prev Rehabil. 2008; 15: 83-88. (Pubitemid 351263260)
35. Peters HW, Westendorp IC, Hak AE, et al. Menopausal status and risk factors for cardiovascular disease. J Intern Med. 1999; 246: 521-528. (Pubitemid 30003172)
36. Farish E, Fletcher CD, Hart DM, Smith ML. Effects of bilateral oophorectomy on lipoprotein metabolism. Br J Obstet Gynaecol. 1990; 97: 78-82. (Pubitemid 20136134)
37. Lip GY, Blann AD, Jones AF, Beevers DG. Effects of hormone- replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am Heart J. 1997; 134: 764-771.
38. Gambacciani M, Ciaponi M, Cappagli B, Benussi C, De Simone L, Genazzani AR. Climacteric modifications in body weight and fat tissue distribution. Climacteric. 1999; 2: 37-44. (Pubitemid 29253924)
39. Shaw LJ, Bairey Merz CN, Pepine CJ, et al. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol. 2006; 47 (3 Suppl): S4-S20.
40. Heller RF, Jacobs HS. Coronary heart disease in relation to age, sex, and the menopause. Br Med J. 1978; 1: 472-474. (Pubitemid 8318840)
41. Hormones, cardiovascular health in women. Hum Reprod Update. 2006; 12: 483-497.
42. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med. 1976; 85: 447-452.
43. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause. 2006; 13: 265-279. (Pubitemid 43755881)
44. van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet. 1996; 347: 714-718. (Pubitemid 26085645)
45. Jacobsen BK, Nilssen S, Heuch I, Kvale G. Does age at natural menopause affect mortality from ischemic heart disease? J Clin Epidemiol. 1997; 50: 475-479.
46. Mondul AM, Rodriguez C, Jacobs EJ, Calle EE. Age at natural menopause and cause-specific mortality. Am J Epidemiol. 2005; 162: 1089-1097. (Pubitemid 41746621)
47. Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med. 1999; 159: 1061-1066. (Pubitemid 29230857)
48. Antonopoulos A, Kyriacou C, Kazianis G. Significance of endothelin- 1 in myocardial infarction. Hellenic J Cardiol. 2007; 48: 161-164.
49. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002; 39: 257-265.
50. Doshi SN, Naka KK, Payne N, et al. Flow-mediated dilatation following wrist and upper arm occlusion in humans: the contribution of nitric oxide. Clin Sci (Lond). 2001; 101: 629-635. (Pubitemid 33135344)
51. Gokce N, Keaney JF, Jr, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol. 2003; 41: 1769-1775. (Pubitemid 36584251)
52. Shimbo D, Grahame-Clarke C, Miyake Y, et al. The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis. 2007; 192: 197-203. (Pubitemid 46602298)
53. Bush DE, Jones CE, Bass KM, Walters GK, Bruza JM, Ouyang P. Estrogen replacement reverses endothelial dysfunction in postmenopausal women. Am J Med. 1998; 104: 552-558. (Pubitemid 28328768)
54. Sorensen KE, Dorup I, Hermann AP, Mosekilde L. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation. 1998; 97: 1234-1238. (Pubitemid 28169174)
55. Colacurci N, Manzella D, Fornaro F, Carbonella M, Paolisso G. Endothelial function and menopause: effects of raloxifene administration. J Clin Endocrinol Metab. 2003; 88: 2135-2140. (Pubitemid 36549889)
56. Rossi R, Nuzzo A, Origliani G, Modena MG. Prognostic role of flow-mediated dilation and cardiac risk factors in post-menopausal women. J Am Coll Cardiol. 2008; 51: 997-1002. (Pubitemid 351318128)
57. Vitale C, Mercuro G, Cerquetani E, et al. Time since menopause influences the acute and chronic effect of estrogens on endothelial function. Arterioscler Thromb Vasc Biol. 2008; 28: 348-352. (Pubitemid 351161210)
58. Pinto S, Virdis A, Ghiadoni L, et al. Endogenous estrogen and acetylcholine-induced vasodilation in normotensive women. Hypertension. 1997; 29 (1 Pt 2): 268-273. (Pubitemid 27074054)
59. Virdis A, Ghiadoni L, Pinto S, et al. Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women. Circulation. 2000; 101: 2258-2263. (Pubitemid 30317127)
60. Ohmichi M, Kanda Y, Hisamoto K, et al. Rapid changes of flow-mediated dilatation after surgical menopause. Maturitas. 2003; 44: 125-131. (Pubitemid 36173970)
61. Hashimoto M, Akishita M, Eto M, et al. Modulation of endothelium- dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation. 1995; 92: 3431-3435. (Pubitemid 26360544)
62. Williams MR, Westerman RA, Kingwell BA, et al. Variations in endothelial function and arterial compliance during the menstrual cycle. J Clin Endocrinol Metab. 2001; 86: 5389-5395.
63. Hamelin BA, Methot J, Arsenault M, et al. Influence of the menstrual cycle on the timing of acute coronary events in premenopausal women. Am J Med. 2003; 114: 599-602. (Pubitemid 36577263)
64. Kalantaridou SN, Naka KK, Bechlioulis A, Makrigiannakis A, Michalis L, Chrousos GP. Premature ovarian failure, endothelial dysfunction and estrogen-progestogen replacement. Trends Endocrinol Metab. 2006; 17: 101-109.
65. Kalantaridou SN, Naka KK, Papanikolaou E, et al. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J Clin Endocrinol Metab. 2004; 89: 3907-3913. (Pubitemid 39071493)
66. Bairey Merz CN, Johnson BD, Sharaf BL, et al. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. J Am Coll Cardiol. 2003; 41: 413-419.
67. Rickenlund A, Eriksson MJ, Schenck-Gustafsson K, Hirschberg AL. Amenorrhea in female athletes is associated with endothelial dysfunction and unfavorable lipid profile. J Clin Endocrinol Metab. 2005; 90: 1354-1359. (Pubitemid 40463987)
68. Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 1994; 121: 936-941. (Pubitemid 24370856)
69. McCrohon JA, Adams MR, McCredie RJ, et al. Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women. Clin Endocrinol (Oxf). 1996; 45: 435-441.
70. Koh KK, Blum A, Hathaway L, et al. Vascular effects of estrogen and vitamin E therapies in postmenopausal women. Circulation. 1999; 100: 1851-1857. (Pubitemid 29511137)
71. Vehkavaara S, Hakala-Ala-Pietila T, Virkamaki A, et al. Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation. 2000; 102: 2687-2693. (Pubitemid 30949244)
72. Koh KK, Jin DK, Yang SH, et al. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation. 2001; 103: 1961-1966.
73. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation. 2001; 104: 1773-1778. (Pubitemid 32963341)
74. de Kleijn MJ, Wilmink HW, Bots ML, et al. Hormone replacement therapy and endothelial function. Results of a randomized controlled trial in healthy postmenopausal women. Atherosclerosis. 2001; 159: 357-365.
75. Guzic-Salobir B, Keber I, Seljeflot I, Arnesen H, Vrabic L. Combined hormone replacement therapy improves endothelial function in healthy postmenopausal women. J Intern Med. 2001; 250: 508-515. (Pubitemid 34008761)
76. Sanada M, Higashi Y, Nakagawa K, et al. A comparison of lowdose and standard-dose oral estrogen on forearm endothelial function in early postmenopausal women. J Clin Endocrinol Metab. 2003; 88: 1303-1309. (Pubitemid 36337794)
77. Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. Arterioscler Thromb Vasc Biol. 2004; 24: 571-576. (Pubitemid 38326155)
78. Sumino H, Ichikawa S, Ohyama Y, et al. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women. Am J Cardiol. 2005; 96: 148-153. (Pubitemid 40853961)
79. Gerhard M, Walsh BW, Tawakol A, et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation. 1998; 98: 1158-1163. (Pubitemid 28436164)
80. Vitale C, Fini M, Leonardo F, et al. Effect of estradiol valerate alone or in association with cyproterone acetate upon vascular function of postmenopausal women at increased risk for cardiovascular disease. Maturitas. 2001; 40: 239-245. (Pubitemid 33124375)
81. Kawano H, Yasue H, Hirai N, et al. Effects of transdermal and oral estrogen supplementation on endothelial function, inflammation and cellular redox state. Int J Clin Pharmacol Ther. 2003; 41: 346-353. (Pubitemid 36980564)
82. Teede HJ, Liang YL, Kotsopoulos D, Zoungas S, Cravent R, McGrath BP. A placebo-controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: effects on arterial compliance and endothelial function. Clin Endocrinol (Oxf). 2001; 55: 673-682. (Pubitemid 34204451)
83. Kernohan AF, Spiers A, Sattar N, et al. Effects of low-dose continuous combined HRT on vascular function in women with type 2 diabetes. Diab Vasc Dis Res. 2004; 1: 82-88.
84. Sherwood A, Bower JK, McFetridge-Durdle J, Blumenthal JA, Newby LK, Hinderliter AL. Age moderates the shortterm effects of transdermal 17β-estradiol on endothelium-dependent vascular function in postmenopausal women. Arterioscler Thromb Vasc Biol. 2007; 27: 1782-1787. (Pubitemid 47207174)
85. Jonason T, Henriksen E, Kangro T, Vessby B, Ringqvist I. Menopause is associated with the stiffness of the common carotid artery in 50-year-old women. Clin Physiol. 1998; 18: 149-155. (Pubitemid 128670108)
86. McGrath BP, Liang YL, Teede H, Shiel LM, Cameron JD, Dart A. Age-related deterioration in arterial structure and function in postmenopausal women: impact of hormone replacement therapy. Arterioscler Thromb Vasc Biol. 1998; 18: 1149-1156. (Pubitemid 28323600)
87. Kallikazaros I, Tsioufis C, Zambaras P, Stefanadis C, Toutouzas P. Conjugated estrogen administration improves common carotid artery elastic properties in normotensive postmenopausal women. Clin Cardiol. 2002; 25: 167-172. (Pubitemid 34263957)
88. Hayward CS, Knight DC, Wren BG, Kelly RP. Effect of hormone replacement therapy on non-invasive cardiovascular haemodynamics. J Hypertens. 1997; 15: 987-993. (Pubitemid 27399813)
89. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999; 340: 1801-1811. (Pubitemid 29266405)
90. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res. 2002; 53: 605-619. (Pubitemid 34175253)
91. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005; 308: 1583-1587. (Pubitemid 40807497)
92. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1997; 17: 217-221.
93. Clarkson TB, Anthony MS, Morgan TM. Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J Clin Endocrinol Metab. 2001; 86: 41-47. (Pubitemid 32109773)
94. Hanke H, Hanke S, Bruck B, et al. Inhibition of the protective effect of estrogen by progesterone in experimental atherosclerosis. Atherosclerosis. 1996; 121: 129-138. (Pubitemid 26074215)
95. Walsh BA, Mullick AE, Banka CE, Rutledge JC. 17betaestradiol acts separately on the LDL particle and artery wall to reduce LDL accumulation. J Lipid Res. 2000; 41: 134-141.
96. Strehlow K, Rotter S, Wassmann S, et al. Modulation of an- tioxidant enzyme expression and function by estrogen. Circ Res. 2003; 93: 170-177. (Pubitemid 36919705)
97. St Clair RW. Effects of estrogens on macrophage foam cells: a potential target for the protective effects of estrogens on atherosclerosis. Curr Opin Lipidol. 1997; 8: 281-286.
98. Elhage R, Arnal JF, Pieraggi MT, et al. 17 beta-estradiol prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 1997; 17: 2679-2684. (Pubitemid 28016008)
99. Caulin-Glaser T, Watson CA, Pardi R, Bender JR. Effects of 17beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest. 1996; 98: 36-42. (Pubitemid 26243818)
100. Caulin-Glaser T, Farrell WJ, Pfau SE, et al. Modulation of circulating cellular adhesion molecules in postmenopausal women with coronary artery disease. J Am Coll Cardiol. 1998; 31: 1555-1560. (Pubitemid 28273298)
101. Stork S, von Schacky C, Angerer P. The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. Atherosclerosis. 2002; 165: 301-307. (Pubitemid 35333356)
102. Mori M, Tsukahara F, Yoshioka T, Irie K, Ohta H. Suppression by 17beta-estradiol of monocyte adhesion to vascular endothelial cells is mediated by estrogen receptors. Life Sci. 2004; 75: 599-609. (Pubitemid 38670266)
103. Stork S, Baumann K, von Schacky C, Angerer P. The effect of 17 beta-estradiol on MCP-1 serum levels in postmenopausal women. Cardiovasc Res. 2002; 53: 642-649. (Pubitemid 34175257)
104. Haynes MP, Russell KS, Bender JR. Molecular mechanisms of estrogen actions on the vasculature. J Nucl Cardiol. 2000; 7: 500-508. (Pubitemid 30831182)
105. Kelly MJ, Levin ER. Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab. 2001; 12: 152-156. (Pubitemid 33713555)
106. Mendelsohn ME. Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol. 2002; 90 (1A): 3F-6F.
107. Sudoh N, Toba K, Akishita M, et al. Estrogen prevents oxidative stress-induced endothelial cell apoptosis in rats. Circulation. 2001; 103: 724-729. (Pubitemid 32144202)
108. Iwakura A, Luedemann C, Shastry S, et al. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation. 2003; 108: 3115-3121. (Pubitemid 38031801)
109. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991; 325: 1196-1204.
110. Kim CJ, Ryu WS, Kwak JW, Park CT, Ryoo UH. Changes in Lp(a) lipoprotein and lipid levels after cessation of female sex hormone production and estrogen replacement therapy. Arch Intern Med. 1996; 156: 500-504.
111. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab. 2003; 88: 2470-2478. (Pubitemid 36724411)
112. Koh KK, Mincemoyer R, Bui MN, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med. 1997; 336: 683-690. (Pubitemid 27102682)
113. Phillips LS, Langer RD. Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. Fertil Steril. 2005; 83: 558-566. (Pubitemid 40348564)
114. Hanke H, Kamenz J, Hanke S, et al. Effect of 17-beta estradiol on pre-existing atherosclerotic lesions: role of the endothelium. Atherosclerosis. 1999; 147: 123-132. (Pubitemid 29486781)
115. Rosenfeld ME, Kauser K, Martin-McNulty B, Polinsky P, Schwartz SM, Rubanyi GM. Estrogen inhibits the initiation of fatty streaks throughout the vasculature but does not inhibit intra-plaque hemorrhage and the progression of established lesions in apolipoprotein E deficient mice. Atherosclerosis. 2002; 164: 251-259. (Pubitemid 35223074)
116. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo- controlled trial. Ann Intern Med. 2001; 135: 939-953.
117. Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Small low-density lipoprotein particles and endotheliumdependent vasodilation in postmenopausal women. Atherosclerosis. 2004; 177: 329-336.
118. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation. 1999; 100: 717-722. (Pubitemid 29383641)
119. Miller AP, Chen YF, Xing D, Feng W, Oparil S. Hormone replacement therapy and inflammation: interactions in cardiovascular disease. Hypertension. 2003; 42: 657-663. (Pubitemid 37237305)
120. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA. 2002; 288: 980-987.
121. Silvestri A, Gebara O, Vitale C, et al. Increased levels of Creactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation. 2003; 107: 3165-3169. (Pubitemid 36793086)
122. Hu P, Greendale GA, Palla SL, et al. The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial. Atherosclerosis. 2006; 185: 347-352. (Pubitemid 43306748)
123. Venugopal SK, Devaraj S, Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens. 2005; 14: 33-37. (Pubitemid 40110697)
124. Jialal I, Devaraj S, Singh U. C-reactive protein and the vascular endothelium: implications for plaque instability. J Am Coll Cardiol. 2006; 47: 1379-1381.
125. Zanger D, Yang BK, Ardans J, et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol. 2000; 36: 1797-1802. (Pubitemid 30844087)
126. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002; 90: 251-262.
127. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation. 1994; 89: 1501-1510. (Pubitemid 24114224)
128. Post WS, Goldschmidt-Clermont PJ, Wilhide CC, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res. 1999; 43: 985-991.
129. Evans MJ, Eckert A, Lai K, Adelman SJ, Harnish DC. Reciprocal antagonism between estrogen receptor and NF-kappaB activity in vivo. Circ Res. 2001; 89: 823-830. (Pubitemid 34633854)
130. Koh KK, Yoon BK. Controversies regarding hormone therapy: Insights from inflammation and hemostasis. Cardiovasc Res. 2006; 70: 22-30.
131. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996; 335: 453-461. (Pubitemid 26269944)
132. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med. 2002; 137: 273-284. (Pubitemid 34898558)
133. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004; 291: 1701-1712. (Pubitemid 38489892)
134. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007; 356: 2591-2602.
135. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297: 1465-1477. (Pubitemid 46556472)
136. Manson JE, Bassuk SS. Invited commentary: Hormone therapy and risk of coronary heart disease - Why renew the focus on the early years of menopause? Am J Epidemiol. 2007; 166: 511-517.
137. Alexandersen P, Tanko LB, Bagger YZ, Qin G, Christiansen C. The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric. 2006; 9: 108-118.
138. Salpeter SR, Walsh JME, Greyber E, Salpeter EE. Coronary heart disease events associated with hormone therapy in younger and older women. J Gen Intern Med. 2006; 21: 363-366.
139. Lobo RA. Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials. Arch Intern Med. 2004; 164: 482-484.
140. van der Schouw YT, Grobbee DE. Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy. Eur Heart J. 2005; 26: 1358-1361.
141. Leal M, Diaz J, Serrano E, Abellan J, Carbonell LF. Hormone replacement therapy for oxidative stress in postmenopausal women with hot flushes. Obstet Gynecol. 2000; 95: 804-809.
142. Gast GCM, Grobbee DE, Pop VJM, et al. Menopausal complaints are associated with cardiovascular risk factors. Hypertension. 2008; 51: 1-7.
143. Le Gal G, Gourlet V, Hogrel P, Plu-Bureau G, Touboul PJ, Scarabin PY. Hormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) study. Atherosclerosis. 2003; 166: 163-170.
144. Angerer P, Stork S, Kothny W, Schmitt P, von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol. 2001; 21: 262-268. (Pubitemid 32125376)
145. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6. 8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002; 288: 49-57.
146. Furberg CD, Vittinghoff E, Davidson M, et al. Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned. Circulation. 2002; 105: 917-922. (Pubitemid 34184567)
147. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002; 288: 2432-2440. (Pubitemid 35340539)
148. Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 2003; 349: 535-545. (Pubitemid 36951365)
149. Recommendations for estrogen, progestogen use in peri-and postmenopausal women. October 2004 position statement of The North American Menopause Society. Menopause. 2004; 11: 589-600.
150. Skouby SO, Al-Azzawi F, Barlow D, et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/ 2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas. 2005; 51: 8-14.
151. Estrogen, progestogen use in peri- and postmenopausal women. March 2007 position statement of The North American Menopause Society. Menopause. 2007; 14: 168-182.
152. Stork S, van der Schouw YT, Grobbee DE, Bots ML. Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. Trends Endocrinol Metab. 2004; 15: 66-72. (Pubitemid 38253008)
153. Rossouw JE. Coronary heart disease in menopausal women: implications of primary and secondary prevention trials of hormones. Maturitas. 2005; 51: 51-63.
154. Holm P, Andersen HL, Andersen MR, Erhardtsen E, Stender S. The direct antiatherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium. A time course study in cholesterol-clamped rabbits. Circulation. 1999; 100: 1727-1733.
155. Rosano GM, Vitale C, Silvestri A, Fini M. Metabolic and vascular effect of progestins in post-menopausal women. Implications for cardioprotection. Maturitas. 2003; 46 (Suppl 1): S17-29.
156. Role of progestogen in hormone therapy for postmenopausal women. position statement of The North American Menopause Society. Menopause. 2003; 10: 113-132. (Pubitemid 36705516)
157. Otsuki M, Saito H, Xu X, et al. Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2001; 21: 243-248. (Pubitemid 32125373)
158. Teede HJ, McGrath BP, Smolich JJ, et al. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol. 2000; 20: 1404-1409. (Pubitemid 30262946)
159. Sumino H, Ichikawa S, Sawada Y, et al. Effects of hormone replacement therapy on blood coagulation and fibrinolysis in hypertensive and normotensive postmenopausal women. Thromb Res. 2005; 115: 359-366. (Pubitemid 40283478)
160. Kimmerle R, Heinemann L, Heise T, et al. Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women. Menopause. 1999; 6: 36-42. (Pubitemid 29131757)
161. Soranna L, Cucinelli F, Perri C, et al. Individual effect of E2 and dydrogesterone on insulin sensitivity in post-menopausal women. J Endocrinol Invest. 2002; 25: 547-550. (Pubitemid 34661844)
162. Saglam K, Polat Z, Yilmaz MI, Gulec M, Akinci SB. Effects of postmenopausal hormone replacement therapy on insulin resistance. Endocrine. 2002; 18: 211-214. (Pubitemid 35239782)
163. Catalano D, Trovato GM, Spadaro D, et al. Insulin resistance in postmenopausal women: concurrent effects of hormone replacement therapy and coffee. Climacteric. 2008; 11: 373-382.
164. Harman SM, Brinton EA, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric. 2005; 8: 3-12. (Pubitemid 40675116)
165. ELITE. Early versus late intervention trial with estradiol [Internet]. Available from: http://www.clinicaltrials.gov/ct/show/NCT00114517
166. Christodoulakos GE, Panoulis CP, Lambrinoudaki IV, et al. The effect of hormone therapy and raloxifene on serum matrix metalloproteinase-2 and -9 in postmenopausal women. Menopause. 2004; 11: 299-305. (Pubitemid 40362184)